Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!"

Journal of Psychiatric Practice

Volumn 13, Issue 5, 2007, Pages 328-333

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; BENZATROPINE; CITALOPRAM; CREATINE KINASE; CYTOCHROME P450 2D6; FLUOXETINE; LITHIUM; PAROXETINE; PERPHENAZINE; TRAZODONE; VENLAFAXINE;

ADULT; BIPOLAR DISORDER; CASE REPORT; DELIRIUM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTHERMIA; HYPOMANIA; LEUKOCYTOSIS; MUSCLE RIGIDITY; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; REVIEW; TREATMENT RESPONSE;

BENZTROPINE; BIPOLAR DISORDER; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PAROXETINE; PERPHENAZINE; PSYCHOTROPIC DRUGS; TRAZODONE;

EID: 34748822938     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000290671.94859.65     Document Type: Review

References (35)

1. Preskorn SH, Lacey RL. Polypharmacy. When is it rational? J Psychiatr Pract 2007;13:97-105.
2. Preskorn SH, Flockhart DA. 2006 guide to psychiatric drug interactions. Primary Psychiatry 2006;13:35-64.
3. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
4. Walley T, Pirmohamed M, Proudlove C, et al. Interaction of metoprolol and fluoxetine. Lancet 1993;341:967-8.
5. Shad MU, Preskorn SH. Drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. J Clin Pharmacol 1999;19:471-2.
6. Bertschy G, Baumann PA, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
7. Preskorn SH. Mania in a case of polypsychopharmacology: Pharmacodynamic and pharmacokinetic considerations: Do you believe in magic? J Psychiatr Pract 2007;13:178-83.
8. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15
9. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: part II: Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26
10. Young C. A case of neuroleptic malignant syndrome and serotonin disturbance (letter to the editor). J Clin Psychopharmacol 1997;17:65-6.
11. Janicak P, Davis J, Preskorn S, et al., eds. Principles and practice of psychopharmacotherapy, 3rd edition. Baltimore: Williams & Wilkins; 2001.
12. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990;253:803-11.
13. Curzon G, Kennett GA. mCPP: A tool for studying behavioral responses associated with 5-HT1c receptors. Trends Pharmacol Sci 1990;11:181-2.
14. Kennett GA, Wood MD, Glen A, et al. In vivo properties of SB 2000646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 1994;111:797-802.
15. Preskorn S. Why did Terry fall off the dose-response curve? J Pract Psychiatry Behav Health 1996;2:39-43.
16. Harvey A, Preskorn S. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors Part I. J Clin Psychopharmacol 1996;16: 273-85 and Part II 16:345-55.
17. Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996;42:573-81.
18. Dahl-Puustinen ML, Liden A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
19. Preskorn S. Have you phenotyped your patient lately? J Pract Psychiatry Behav Health 1996;2:115-7.
20. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-8.
21. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-36.
22. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
23. Dayer P, Leemann T, Striberni R. Dextromethorphan Odemethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 1989;45:34-40.
24. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989;80(Suppl 350):60-75.
25. Alderman J, Preskorn S, Greenblatt D, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
26. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978;179:641-68.
27. Mori S, Matsuura T, Takino T, et al. Light and electron microscopic immunohistochemical studies of serotonin nerve fibres in the substantia nigra of the rat, cat and monkey. Anat Embryol 1987;176:13-8.
28. Phillipson OT. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: A horseradish peroxidase study in the rat. J Comp Neurol 1979;187:117-44.
29. Steinbusch HWM; Björklund A, Hökfelt T, et al., eds. Serotonin-immunoreactive neurons and their projections in the CNS. Handbook of chemical neuroanatomy. Part II. Classical transmitters and transmitter receptors in the CNS. Amsterdam: Elsevier; 1984:68-125.
30. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Brit J Pharm 1995;116:1923-31.
31. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-34.
32. Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 1994;55:492-5.
33. Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psychiatr Pract 2002;8:233-8.
34. Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. J Psychiatr Pract 2002;8:370-6.
35. Preskorn SH. Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. J Psychiatr Pract 2003;9:71-8.